our capabilities

Uniquely integrated formulation, device and development capabilities

We effectively integrate all technologies and disciplines required to deliver an inhaled product.

ANNUAL REPORT 2018

AR18_mockup.png

Annual Report and Accounts for the year ended 31 December 2018

Read more
Investment case
1

Differentiated inhalation development capabilities

2

In-market product cash flow generation

3

Focused R&D strategy with pipeline progression and partnering potential

4

Focus on Operational Excellence

5

Strong cash flow generation and capital discipline